Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 4,085 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Steroid treatment Clear all
Completed Phase 2 Interventional

Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis

NCT00021294
View directory record Official record
Conditions
Non-melanomatous Skin Cancer, Precancerous/Nonmalignant Condition
Interventions
eflornithine, triamcinolone
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 16, 2026, 4:42 AM EDT
Recruiting Not applicable Interventional

5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy

NCT04288427
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Prostate Hyperplasia, Prostate Disease, Prostate Hypertrophy, Prostate Pain, Lower Urinary Tract Symptoms, Urinary Obstruction, Urinary Tract Disease
Interventions
Finasteride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 16, 2026, 4:42 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

NCT03748641
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer
Interventions
Niraparib, Abiraterone Acetate, Prednisone, Placebo, New Formulation of Niraparib and Abiraterone Acetate (AA)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
765 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
47
States / cities
Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 16, 2026, 4:42 AM EDT
Terminated Phase 2 Interventional Results available

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT02419469
View directory record Official record
Conditions
Leukemia, Precursor-B Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Lymphoma
Interventions
Cytarabine, Daunorubicin, Vincristine, Prednisone, PEG asparaginase, Ofatumumab, Rituximab, Methotrexate, Cyclophosphamide, Mercaptopurine, Doxorubicin, Dexamethasone acetate, Thioguanine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 16, 2026, 4:42 AM EDT
Terminated Phase 2 Interventional Results available

Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)

NCT01212588
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
mifepristone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 64 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 16, 2026, 4:42 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT01832727
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Oprozomib, Dexamethasone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • Westwood, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 16, 2026, 4:42 AM EDT
Terminated Phase 1Phase 2 Interventional

Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD

NCT00032773
View directory record Official record
Conditions
Acute Graft Versus Host Disease
Interventions
pentostatin for injection
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
6 Months and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 16, 2026, 4:42 AM EDT
Completed Phase 3 Interventional Results available

Exercise and Testosterone Therapy in Elderly Men With Physical Frailty

NCT00345969
View directory record Official record
Conditions
Physical Frailty, Hip Fracture, Elective Hip Replacement, Hypogonadism
Interventions
Transdermal Testosterone gel (1%), Supervised exercise training
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 16, 2026, 4:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vitamin D for the Treatment of Women With Polycystic Ovary Syndrome (PCOS)

NCT00907153
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Vitamin D, Placebo
Dietary Supplement · Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 16, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer

NCT00404066
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
Lapatinib, Doxorubicin, Cyclophosphamide, Docetaxel, Pegfilgrastim, Filgrastim, Dexamethasone, Trastuzumab
Drug
Lead sponsor
George Albert Fisher
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
San Jose, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 16, 2026, 4:42 AM EDT
Completed Phase 4 Interventional

Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents

NCT03279328
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Topical Steroid Ointment, Vaseline, Skin Barrier Moisturier
Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 16, 2026, 4:42 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation

NCT00609739
View directory record Official record
Conditions
Leukemia
Interventions
cyclosporine, cytarabine, filgrastim, methotrexate, methylprednisolone, mitoxantrone hydrochloride, allogeneic bone marrow transplantation, umbilical cord blood transplantation, Cis-Retinoic acid
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 16, 2026, 4:42 AM EDT
Completed Phase 1 Interventional

Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy

NCT03883919
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas
Interventions
5-FU, Leucovorin, Liposomal Irinotecan, Paricalcitol, Serum and plasma blood samples, Tumor biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 16, 2026, 4:42 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption

NCT03115567
View directory record Official record
Conditions
Acneiform Rash, Papulopustular Eruption
Interventions
Triamcinolone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 16, 2026, 4:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Timing Estrogen After MenoPaUSe

NCT01605071
View directory record Official record
Conditions
Insulin Resistance
Interventions
Estradiol
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Oct 16, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale

NCT00394771
View directory record Official record
Conditions
Breakthrough Bleeding
Interventions
DR-1031, Seasonale®, Portia®
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
567 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
50
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 16, 2026, 4:42 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma

NCT02605356
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Bortezomib, Dexamethasone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Encinitas, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 16, 2026, 4:42 AM EDT
Completed Not applicable Interventional Results available

Epidural Lavage Study for Lumbar Stenosis

NCT03511053
View directory record Official record
Conditions
Lumbar Spinal Stenosis
Interventions
Epidural Steroid Injection with Lavage
Procedure
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 16, 2026, 4:42 AM EDT
Completed Phase 2 Interventional

Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer

NCT00003753
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
dexamethasone, floxuridine, irinotecan hydrochloride, adjuvant therapy, conventional surgery
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 16, 2026, 4:42 AM EDT
Completed Not applicable Interventional

Study for Treatment of Cancer in Children With Ataxia-telangiectasia

NCT00187057
View directory record Official record
Conditions
Ataxia-Telangiectasia
Interventions
vinblastine, vincristine, prednisone, daunorubicin, doxorubicin, methotrexate, cyclophosphamide, L-asparaginase, etoposide, cytarabine, mercaptopurine, dexamethasone, procarbazine, chemotherapy, intrathecal chemotherapy, steroid therapy
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 10 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 27, 2015 · Synced Oct 16, 2026, 4:42 AM EDT
Not listed Phase 4 Interventional

EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone

NCT03781596
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Retrospective evaluation of endoscopy prior to study drug, Symptom Survey, Medication Compliance Phone Call, Endoscopy while on study drug, Fluticasone, Omeprazole, Placebo oral capsule
Diagnostic Test · Other · Drug
Lead sponsor
Claire Daniels
Federal
Eligibility
6 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 16, 2026, 4:42 AM EDT
Terminated Phase 2 Interventional Results available

Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

NCT03457142
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Abatacept, Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Buffalo, New York • East Hills, New York • West Islip, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 16, 2026, 4:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease

NCT01578473
View directory record Official record
Conditions
Peyronie's Disease
Interventions
Vitamin D2, Vitamin E, Testosterone Pellets
Drug
Lead sponsor
Men's Health Boston
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 16, 2026, 4:42 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

NCT00430677
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Corticosteroids (prednisone or prednisolone), Abatacept, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2015 · Synced Oct 16, 2026, 4:42 AM EDT